India Pharma Outlook Team | Saturday, 16 March 2024
Sibylla Biotech declared a drug discovery joint pact with Osaka-settled Ono pharma for getting to Sibylla's state-of-the-art Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) innovation to distinguish and foster candidates for Multiple therapeutic focuses in the field of central nervous system (CNS).
Under the terms of the agreement, Sibylla is entitled to a total contract value in the three-digit millions of US dollars, which includes an upfront payment, research, development, and sales milestones, as well as sales royalties. Further financial information about the agreement has not been published.
Sibylla Biotech uses their PPI-FIT technology to create Folding Interfering Degraders. Small compounds known as FIDs interfere with the folding mechanism of a target protein, causing it to degrade. The method focuses on specific proteins, notably those deemed "undruggable" due to the lack of appropriate pockets in their natural condition.
“Sibylla's PPI-FIT technology platform has the potential to surpass the limitations of conventional methods and uncover novel CNS therapeutic targets,” said Toichi Takino, senior executive officer/executive director, discovery & research of Ono Pharmaceutical. “This collaboration is a key part of our strategy to increase efficiency in developing our pipeline in CNS areas and bring innovative solutions to patients facing serious neurological disorders.”
“Our partnership with Ono Pharmaceutical represents a fusion of Sibylla's cutting-edge technology in protein folding simulation with Ono's extensive experience in CNS research. Together, we aim to unlock new therapeutic possibilities for patients worldwide,” commented Lidia Pieri, PhD, co-founder and chief executive officer of Sibylla Biotech. “I am honored to collaborate with the Ono Pharmaceutical team, whose rich history, expertise and culture I greatly appreciate, and all of us at Sibylla look forward to working closely with them.”
.jpg)
